Yahoo Finance 
Diuretics Global Market Report 2023
Major players in the diuretic market are Merck & Co., Meda Manufacturing GmbH, Pfizer Inc., Glaxosmithkline, Roche, Aton Pharma Inc., BoehringerIngelheim GmbH, Novartis AG and Teva Pharmaceuticals Industries Ltd.
New York, Feb. 20, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Diuretics Global Market Report 2023" - https://www.reportlinker.com/p06245017/?utm_source=GNW
The global diuretics market will grow from $0.64 billion in 2022 to $0.67 billion in 2023 at a compound annual growth rate (CAGR) of 4.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The diuretics market is expected to grow to $0.75 billion in 2027 at a CAGR of 2.9%.
The diuretic drugs market consists of sales of diuril, microzide, and indapamide.Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.
The value of goods in this market includes related services sold by the creators of the goods.
Diuretic drugs refer to the drugs that help increase the flow of urine by reducing the concentration of sodium and chloride in the body. It helps the body eliminate salt (sodium) and water with these so-called "water tablets." Diuretic drugs include diuril, microzide, indapamide.
North America is the largest region in the diuretic market in 2022.Middle East is expected to be the fastest growing region in the forecast period.
The regions covered in the diuretic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main types of diuretic are osmotic diuretics, carbonic anhydrase inhibitors, loop diuretics, thiazides & thiazide-like diuretics and aldosterone antagonists.An osmotic diuretic is a form of diuretic that prevents water and sodium from being reabsorbed.
They are intravenously administered pharmacologically inactive compounds.The different routes of administration include intravenous, and oral and are used in hypertension, glaucoma, heart failure, and kidney stones.
It is distributed through various channels such as hospital pharmacies, independent pharmacies, retail pharmacies, drug stores, and online pharmacies.
The increase in renal and kidney disorder cases drives the diuretics drug market.In such cases, the kidney does not function properly increases the need for water pills (diuretic drugs) to maintain a proper flow of urine.
The rise in kidney disorders can be attributed to changes in lifestyle such as the consumption of unhealthy food high in calcium and other minerals.For example, in 2021, according to the Centers For Disease Control and Prevention, a US-based government agency, more than 1 in 7 people, that is 15% of US adults,approximately 37 million people, are suffering from chronic kidney diseases.
Therefore, increase in renal and kidney disorder cases drives the diuretics market.
The diuretic drugs market is restricted by the stringent regulatory policies governing the market.Several requirements are laid down by the regulatory bodies to manufacture, process, and pack the drugs and the companies should abide by various compliances such as FDA’s CGMP regulations; Compliance with European Medicines Agency Regulations, and WHO Guidelines.
For instance, the Current Good Manufacturing Practice (CGMP) regulations of the FDA in the USA impose several regulations under 21 CFR parts 314, 210, and 211, concerning the application and licensing of new and generic drugs, regulations for manufacturing, processing, packaging or holding of drugs, and requirements for finished pharmaceuticals respectively. These regulations negatively impact the growth of the market.
A new drug delivery technology called the oral nanoparticle delivery technology is developed to improve the pH and intestinal permeability of the diuretic drugs to increase the digesting capability as the majority of these drugs have low water solubility and bioavailability.Drugs such as amlodipine and isradipine having low bioavailability (less number of solvents to get diluted) and high light sensitivity were delivered using Nanoemulsion (dispersion that consists of oil, surfactants, and aqueous phase) as a drug delivery system.
Pharmacokinetics (study of how an organism affects a drug) data of both the drugs revealed enhanced stability and bioavailability.For instance, Nanomerics, a pharmaceutical nanotechnology drug delivery company is carrying out R&D in this technology by working on MET (Molecule Envelop Technology) Nanoparticles Oral Delivery.
Also, in 2020, a Japanese research team from Kumamoto University developed a new nanocarrier drug delivery technology to enhance the drugs, from moving from the blood into the brain.
The manufacturers must comply with the European Medicines Agency’s scientific guidelines on the quality that should be maintained in the manufacturing, processing, and packaging of the drugs and help manufacturers prepare marketing authorization applications.In addition, the International Council for Harmonization (ICH) guidelines lay down the Good Manufacturing Practice (ICHQ7) guide which states that all the utilities like steam, gases, compressed air, heating, ventilation, and air condition could impact the quality of the product (drug).
Hence, proper monitoring and actions should be executed if limits are exceeded. It has also framed guidelines for Quality Risk Management (ICHQ9) that provides all the risk management methods and tools like FMEA (Failure Mode Effects Analysis), FMECA (Failure Mode, Effects and Criticality Analysis), FTA (Fault Tree Analysis), HACCP (Hazard Analysis and Critically Control Points) and others.
In March 2020, AstraZeneca, a UK-based pharmaceutical company acquired AtnahsPharma for $350 million.Through this acquisition, AstraZeneca gets the commercial rights to various drugs such as Tenoretic (atenolol, chlorthalidone fixed-dose combination), and Tenormin (atenolol), Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination), Inderal (propranolol) and Zestril (lisinopril).
AtnahsPharma is a UK-based company that develops diuretic drugs.
The countries covered in the diuretic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).
The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.
The diuretic drugs market research report is one of a series of new reports that provides diuretic drugs market statistics, including diuretic drugs industry global market size, regional shares, competitors with a diuretic drugs market share, detailed diuretic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the diuretic drugs industry. This diuretic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Read the full report: https://www.reportlinker.com/p06245017/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
